Abstract
It is well demonstrated that inflammatory processes in the interstitium are pivotal as the pathological features of idiopathic interstitial pneumonia (IIP). Standard therapy with corticosteroids may suppress such inflammatory changes, but not result in marked clinical benefits, especially among patients with idiopathic pulmonary fibrosis (IPF). Recent studies clarified that the degrees of cell infiltration did not correlate with the clinical outcomes, but so-called remodeling processes, such as the number of fibroblastic foci, can more accurately predict the life expectancy among patients with IPF; the most common disease entity with poor prognosis. In accordance with such findings, anti-inflammatory strategies including treatment with corticosteroids, immunosuppressive agents, and even recently studied agent interferon-gamma have not been successful to stop or improve this process. More focuses should be now cast onto the molecular processes of myofibroblastic differentiation, proliferation and apoptosis of lung fibroblasts. Agents regulating these processes may become new therapeutic choices for these progressive pulmonary disorders.
Keywords: idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, lung remodeling, fibroblastic foci, myofibroblast, signal transduction
Current Respiratory Medicine Reviews
Title: Lung Remodeling in Interstitial Pneumonia: A New Molecular Target of Pulmonary Fibrosis
Volume: 1 Issue: 1
Author(s): Mitsuhiro Sunohara and Hajime Takizawa
Affiliation:
Keywords: idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, lung remodeling, fibroblastic foci, myofibroblast, signal transduction
Abstract: It is well demonstrated that inflammatory processes in the interstitium are pivotal as the pathological features of idiopathic interstitial pneumonia (IIP). Standard therapy with corticosteroids may suppress such inflammatory changes, but not result in marked clinical benefits, especially among patients with idiopathic pulmonary fibrosis (IPF). Recent studies clarified that the degrees of cell infiltration did not correlate with the clinical outcomes, but so-called remodeling processes, such as the number of fibroblastic foci, can more accurately predict the life expectancy among patients with IPF; the most common disease entity with poor prognosis. In accordance with such findings, anti-inflammatory strategies including treatment with corticosteroids, immunosuppressive agents, and even recently studied agent interferon-gamma have not been successful to stop or improve this process. More focuses should be now cast onto the molecular processes of myofibroblastic differentiation, proliferation and apoptosis of lung fibroblasts. Agents regulating these processes may become new therapeutic choices for these progressive pulmonary disorders.
Export Options
About this article
Cite this article as:
Sunohara Mitsuhiro and Takizawa Hajime, Lung Remodeling in Interstitial Pneumonia: A New Molecular Target of Pulmonary Fibrosis, Current Respiratory Medicine Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573398052953686
DOI https://dx.doi.org/10.2174/1573398052953686 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Addressing MIST (Metabolites in Safety Testing): Bioanalytical Approaches to Address Metabolite Exposures in Humans and Animals
Current Drug Metabolism Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Editorial: [Hot Topic: Drug Development in Dermatology: New Targets for Old Diseases?]
Current Pharmaceutical Biotechnology Pharmacokinetics of Recombinant Human Endostatin in Rats
Current Drug Metabolism Peripheral Biomarkers to Assess Suicide Risk
Current Psychiatry Reviews The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Role of PGE2 in Blood Pressure Regulation
Current Hypertension Reviews High Frequency of Grossly Deleted nef Genes in HIV-1 Infected Long-Term Slow Progressors Treated with Korean Red Ginseng
Current HIV Research Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Formulation Development and Evaluation of Transdermal 5-Fluorouracil Ethosomal Formulation through 2<sup>5-2</sup> Fractional Factorial Design
Drug Delivery Letters Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Assembly of the Human Immunodeficiency Virus Type I
Current Pharmaceutical Design Changes in the Peripheral Endocannabinoid System as a Risk Factor for the Development of Eating Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Cycloadditions, Cycloisomerizations and Related Reactions of Alkynes Bearing Group 13 or 14 Heteroelements
Current Organic Chemistry Complementary and Alternative Medicine for Childhood Asthma: An Overview of Evidence and Patents
Recent Patents on Inflammation & Allergy Drug Discovery Colloidal Microgels in Drug Delivery Applications
Current Pharmaceutical Design Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents